Literature DB >> 1882828

Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia.

D E Hricik1, J T Mayes, J A Schulak.   

Abstract

To clarify the relative influences of cyclosporine (CsA) therapy, corticosteroid therapy, and other clinical variables on posttransplant hypercholesterolemia, total serum cholesterol levels were measured in 107 renal transplant recipients receiving one of three immunosuppression regimens: CsA and azathioprine (AZA) (group I); CsA, AZA, and prednisone (group II); or AZA and prednisone (group III). Multivariate analysis demonstrated that prednisone therapy, CsA therapy, patient age, and pretransplant cholesterol levels correlated independently with posttransplant cholesterol levels at last follow-up (ranging from 13 to 84 months after transplantation). In 32 patients successfully withdrawn from corticosteroid therapy and maintained on AZA and stable doses of CsA, serum cholesterol decreased from 6.55 +/- 1.1 mmol/L (253.5 +/- 43.1 mg/dL) to 5.27 +/- 1.2 mmol/L (203.9 +/- 45.6 mg/dL). Results of this analysis indicate that prednisone and CsA are independent factors in the pathogenesis of posttransplant hypercholesterolemia. Complete withdrawal of corticosteroids partially corrects hypercholesterolemia in CsA-treated renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1882828     DOI: 10.1016/s0272-6386(12)80095-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  17 in total

Review 1.  Calcineurin inhibitors and post-transplant hyperlipidaemias.

Authors:  R Moore; D Hernandez; H Valantine
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Lipoprotein-apolipoprotein changes in renal transplant recipients.

Authors:  Maurizio Cassader; Gianluca Ruiu; Roberto Gambino; Natalina Alemanno; Giorgio Triolo; Fabrizio Veglia; Gianfranco Pagano
Journal:  Lipids       Date:  2002-10       Impact factor: 1.880

Review 3.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 4.  Primary care of the renal transplant patient.

Authors:  J D Pirsch; R Friedman
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

Review 5.  Impact of medical comorbid disease on antidepressant treatment of major depressive disorder.

Authors:  Dan V Iosifescu; Bettina Bankier; Maurizio Fava
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

Review 6.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 7.  Lipids in liver transplant recipients.

Authors:  Anna Hüsing; Iyad Kabar; Hartmut H Schmidt
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 8.  Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.

Authors:  Titte R Srinivas; Herwig-Ulf Meier-Kriesche
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

Review 9.  Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation.

Authors:  A Tarantino; G Montagnino; C Ponticelli
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

10.  Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation.

Authors:  Kazuyuki Numakura; Hideaki Kagaya; Ryohei Yamamoto; Naoki Komine; Mitsuru Saito; Tsuruta Hiroshi; Susumu Akihama; Takamitsu Inoue; Shintaro Narita; Norihiko Tsuchiya; Tomonori Habuchi; Takenori Niioka; Masatomo Miura; Shigeru Satoh
Journal:  Dis Markers       Date:  2015-04-06       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.